Shares in biotechnology firm CHO Pharma Inc (醣基生醫), which specializes in glycan-based technology platforms, saw brisk trading yesterday during its debut on the Taipei Exchange’s (TPEX) Emerging Stock Board.
The stock jumped to an intraday high of NT$107 from its opening price of NT$50 before closing at NT$83 in its first session with more than 6.38 million shares changing hands.
The company is developing glycan-based antibody and vaccine treatments for a variety of cancers, as well as influenza and autoimmune diseases.
A vaccine for refractory or relapsed follicular lymphoma called CHO-H01 has made the most headway, as the US Food and Drug Administration has given the green light to conduct a phase I clinical trial in the US, which is expected to begin next quarter, the company said.
The company is also developing CHO-A04, a broad-spectrum cancer antibody that is engineered to kill cancer cells in more than 10 cancer types by targeting novel carbohydrate antigens, it said.
The treatments are based on the findings of former Academia Sinica president Wong Chi-huey (翁啟惠), who is recognized as a pioneering researcher in glycoscience and carbohydrate chemistry.
While Wong has been caught in the fallout of the controversy surrounding OBI Pharma Inc (浩鼎), whose breast cancer immunotherapy is also based on his research into carbohydrate antigens, market observers remain upbeat on CHO Pharma Inc’s advantage in the field, where its rivals remain challenged by significant technical barriers.
CHO Pharma reported a net loss of NT$134.57 million (US$4.44 million) in the first half of this year, which widened from a net loss of NT$102.36 million a year earlier.
Separately, EirGenix Inc (台康生技), a joint venture between government agencies and private sector investors, on Tuesday announced that its has received clearance from the Ministry of Economic Affair’s Industrial Bureau to proceed with plans to seek listing on the Taipei Exchange.
The company is focused on biosimilar development and pharmaceutical contract development and manufacturing organization.
It said that EG12014, a biosimilar product that is equivalent to trastuzumab, a monoclonal antibody used to treat breast cancer, completed a phase I clinical trial in Europe earlier this year, and that it is finalizing data collection for phase III studies from more than 200 research centers across 20 countries.
The company said it has also expanded its production output of EG12014 to three 1,000 liter batches, reaching a new milestone in the manufacturing process development, it said, adding that a new production plant at the Hsinchu Science Park is slated to be completed next year.
Taiwan Transport and Storage Corp (TTS, 台灣通運倉儲) yesterday unveiled its first electric tractor unit — manufactured by Volvo Trucks — in a ceremony in Taipei, and said the unit would soon be used to transport cement produced by Taiwan Cement Corp (TCC, 台灣水泥). Both TTS and TCC belong to TCC International Holdings Ltd (台泥國際集團). With the electric tractor unit, the Taipei-based cement firm would become the first in Taiwan to use electric vehicles to transport construction materials. TTS chairman Koo Kung-yi (辜公怡), Volvo Trucks vice president of sales and marketing Johan Selven, TCC president Roman Cheng (程耀輝) and Taikoo Motors Group
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
RECORD-BREAKING: TSMC’s net profit last quarter beat market expectations by expanding 8.9% and it was the best first-quarter profit in the chipmaker’s history Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), which counts Nvidia Corp as a key customer, yesterday said that artificial intelligence (AI) server chip revenue is set to more than double this year from last year amid rising demand. The chipmaker expects the growth momentum to continue in the next five years with an annual compound growth rate of 50 percent, TSMC chief executive officer C.C. Wei (魏哲家) told investors yesterday. By 2028, AI chips’ contribution to revenue would climb to about 20 percent from a percentage in the low teens, Wei said. “Almost all the AI innovators are working with TSMC to address the
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”